InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events

InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On May 30, 2017, InspireMD, Inc. (the Company) announced that the
first two patients in Hong Kong have been successfully treated
with the Companys CGuard EPS carotid stent. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on
Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
99.1 Press release dated May 30, 2017


About InspireMD, Inc. (NYSEMKT:NSPR)

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information

InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session up +0.032 at 0.560 with 964,201 shares trading hands.

An ad to help with our costs